💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Methylhomatropine

CHEMBL1201235 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This antimuscarinic agent acts similarly to atropine but with some differences in potency and selectivity, used historically in eye drops to dilate pupils and in gastrointestinal preparations to reduce spasm and secretions. It blocks the neurotransmitter acetylcholine at muscarinic receptors.

Mécanisme d'action

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(O)c1ccccc1)C2

                

                

                
                

                    
InChI

                    
InChI=1S/C17H24NO3/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12/h3-7,13-16,19H,8-11H2,1-2H3/q+1/t13-,14+,15+,16?

                

                

                

                    
                    

                        
HBD / HBA

                        
- / -

                    

                    
                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This antimuscarinic agent acts similarly to atropine but with some differences in potency and selectivity, used historically in eye drops to dilate pupils and in gastrointestinal preparations to reduce spasm and secretions. It blocks the neurotransmitter acetylcholine at muscarinic receptors.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Methylhomatropine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201235.
                Open-access bioactivity database.
            
        
    • 
        
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.